Role of vitamin D in vascular calcification: bad guy or good guy?

ences between studies may be explained by different doses, types of vitamin D sterols used and treatment duration. Of note, different types of active vitamin D derivatives, when given in high amounts to animals with CKD, are not endowed with the same calcification-inducing capacity. Thus, paricalcitol has been shown to be less pro-calcifying in uraemic rats than calcitriol or doxercalciferol [3, 14]. Whether this also holds true for human patients with CKD remains a matter of debate. No prospective trials are available in such patients comparing the effects of calcitriol with those of the newer active vitamin D derivatives.

[1]  Z. Massy,et al.  FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages , 2012, Osteoporosis International.

[2]  T. Akizawa,et al.  Vitamin D receptor activators inhibit vascular smooth muscle cell mineralization induced by phosphate and TNF-α. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  G. Kundt,et al.  Serum fetuin-A and vitamin D in children with mild-to-severe chronic kidney disease: a cross-sectional study. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  E. Fernández,et al.  Vascular calcification and 25-hydroxyvitamin D levels in non-dialysis patients with chronic kidney disease stages 4 and 5. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  M. Razzaque,et al.  The dualistic role of vitamin D in vascular calcifications. , 2011, Kidney international.

[6]  D. Haffner,et al.  1,25-Dihydroxyvitamin D3-induced aortic calcifications in experimental uremia: up-regulation of osteoblast markers, calcium-transporting proteins and osterix , 2011, Journal of hypertension.

[7]  H. DeLuca,et al.  Is the vitamin d receptor found in muscle? , 2011, Endocrinology.

[8]  A. Levin,et al.  Upregulation of Matrix Metalloproteinase-2 in the Arterial Vasculature Contributes to Stiffening and Vasomotor Dysfunction in Patients With Chronic Kidney Disease , 2009, Circulation.

[9]  Z. Massy,et al.  The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice. , 2009, Atherosclerosis.

[10]  Z. Massy,et al.  Vitamin D affects survival independently of vascular calcification in chronic kidney disease. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[11]  P. Libby,et al.  Arterial and Aortic Valve Calcification Abolished by Elastolytic Cathepsin S Deficiency in Chronic Renal Disease , 2009, Circulation.

[12]  C. Eraldemir,et al.  Serum fetuin--a concentrations are inversely related to cytokine concentrations in patients with chronic renal failure. , 2008, Cytokine.

[13]  L. Chaudhary,et al.  Vitamin D receptor activators can protect against vascular calcification. , 2008, Journal of the American Society of Nephrology : JASN.

[14]  T. Cole,et al.  A bimodal association of vitamin D levels and vascular disease in children on dialysis. , 2008, Journal of the American Society of Nephrology : JASN.

[15]  F. J. Mendoza,et al.  The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. , 2008, Kidney international.

[16]  Z. Al-Aly,et al.  Aortic Msx2-Wnt Calcification Cascade Is Regulated by TNF-&agr;–Dependent Signals in Diabetic Ldlr−/− Mice , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[17]  E. Slatopolsky,et al.  Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. , 2007, Kidney international.

[18]  Jason R. Stubbs,et al.  Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. , 2007, Journal of the American Society of Nephrology : JASN.

[19]  G. London,et al.  Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. , 2007, Journal of the American Society of Nephrology : JASN.

[20]  R. Koerfer,et al.  Vitamin D and vascular calcification , 2007, Current opinion in lipidology.

[21]  A. Kraśniak,et al.  Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  K. Wernecke,et al.  Arterial and cardiac disease in young adults with childhood-onset end-stage renal disease-impact of calcium and vitamin D therapy. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  E. Aguilera-Tejero,et al.  Reversibility of Calcitriol‐Induced Medial Artery Calcification in Rats With Intact Renal Function , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  D. Haffner,et al.  Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3 , 2005, Journal of hypertension.

[25]  N. Stern,et al.  25-Hydroxyvitamin D3-1α-Hydroxylase Is Expressed in Human Vascular Smooth Muscle Cells and Is Upregulated by Parathyroid Hormone and Estrogenic Compounds , 2005, Circulation.

[26]  P. Stenvinkel,et al.  IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly. , 2005, Kidney international.

[27]  P. Price,et al.  Serum Levels of the Fetuin-Mineral Complex Correlate with Artery Calcification in the Rat* , 2004, Journal of Biological Chemistry.

[28]  J. Liao,et al.  1alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. , 2002, Circulation research.

[29]  P. Sarma,et al.  1,25-dihydroxyvitamin D3 receptor is upregulated in aortic smooth muscle cells during hypervitaminosis D. , 2002, Life sciences.

[30]  D. Wheeler,et al.  Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. , 2002, Journal of the American Society of Nephrology : JASN.

[31]  C. Tukaj,et al.  Morphological changes of aortal smooth muscle cells exposed to calcitriol in culture. , 2000, Medical science monitor : international medical journal of experimental and clinical research.

[32]  A. Zinsmeister,et al.  Soft tissue calcification in pediatric patients with end-stage renal disease , 1991, Pediatric Nephrology.

[33]  E. Maccarthy,et al.  1,25‐Dihydroxyvitamin D3 and Rat Vascular Smooth Muscle Cell Growth , 1989, Hypertension.

[34]  M. Haussler,et al.  Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. , 1989, The Journal of clinical investigation.

[35]  E. Ritz,et al.  Demonstration of 1,25(OH)2 vitamin D3 receptors and actions in vascular smooth muscle cellsIn vitro , 1987, Calcified Tissue International.

[36]  R. Garrick.  Klotho Deficiency Causes Vascular Calcification in Chronic Kidney Disease , 2011 .

[37]  A. Covic,et al.  Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. , 1997, Nephron.